Peripheral Diabetic Neuropathy Clinical Trial
Official title:
Immediate and Prolonged Effects of Self-Thai Foot Massage on Pain, Range of Motion and Somatosensory Reception Among Patients With Type 2 Diabetes Peripheral Neuropathy
The goal of this clinical trial is to examine the effect of Self-Thai Foot Massage on type 2 diabetes peripheral neuropathy. The main question is to answer the role of massage in the improvement of peripheral neuropathy. Participants will be taught to perform the Self-Thai Foot Massage every alternate day for 15 days. Researchers will compare the intervention group with the control group (without intervention) to see the improvement in Somatosensory Reception, Range of Motion, and peripheral neuropathy-induced Pain.
Status | Not yet recruiting |
Enrollment | 78 |
Est. completion date | December 1, 2024 |
Est. primary completion date | September 25, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 65 Years |
Eligibility | Inclusion Criteria: - Age range, 40 to 65, to ensure a consistent demographic. - Both genders will be part of the study. - Participants must have a confirmed medical diagnosis of Type 2 Diabetes by the physician and do not have an ulcer or amputation in either foot. - A score on the Ipswich touch test less than 4/6 will be included. - Patients must have a level of glycated hemoglobin HbA1C more than 7. - Individuals receiving treatment for diabetes mellitus, which may include oral hypoglycemic agents, insulin, or both." Exclusion Criteria: - Individuals with pre-existing neurological conditions unrelated to diabetes or peripheral neuropathy. - Participants having severe diabetic complications such as advanced nephropathy, retinopathy or vascular disease will not be included in the study. - Individuals with foot ulcers, infections, or any medical conditions that prevent them from receiving foot massage safely |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Health Sciences Lahore |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Ipswich Touch Test Score (IpTT) | To measure the somatosensory level, Ipswich Touch Test (IpTT) is a reliable and valid test to assess the sensory deficit in diabetic-related neuropathy patients. The highest score is 6. 6/6 means no neuropathy and 0/6 means worse possible neuropathy. | 1 Months | |
Primary | Measure the Range of Motion | Range of motion refers to the extent of movement that can be achieved at a specific joint. In this study, the range of motion of the foot and ankle joints will be measured using goniometry, a technique that involves using a universal goniometer to measure the angles of joint movement. ROM will be assessed for the ankle joint, in degrees of dorsiflexion and plantarflexion. | 1 Months | |
Primary | Measure the intensity of neuropathy induced pain | Pain is defined as "an unpleasant sensory and emotional experience associated with actual or potential tissue damage, reported by patients. In this study pain refers to the unpleasant sensations caused by type 2 diabetes peripheral neuropathy. Pain will be measured through numeric rating pain scale, which ranges from 0 to 10, where "0" represent No Pain and 10 represent worse possible pain. Pain can categorize according to pain score.
Mild pain: A score of 1 to 3 Moderate Pain: A score of 4 to 6. Severe Pain: A score of 7 to 10. |
1 Month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05491850 -
Effects of Moderate Physical Activity on Early Symptoms of Peripheral Diabetic Neuropathy in Type-II Diabetes: A Randomized Clinical Trial
|
N/A | |
Recruiting |
NCT04561609 -
Transcutaneous Application of Gaseous CO2
|
N/A | |
Active, not recruiting |
NCT06131918 -
Assessment of Antioxidant Therapy on Oxidative Stress Biomarkers in Type 2 Diabetic Patients With Neuropathy
|
Phase 2 | |
Completed |
NCT03113448 -
0.075% Capsaicin Lotion for the Treatment of Painful Diabetic Neuropathy
|
Phase 3 | |
Completed |
NCT01293461 -
Safety and Pharmacokinetics of CBX129801 in Patients With Type 1 Diabetes
|
Phase 1/Phase 2 |